Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omeprazole + sodium bicarbonate is an oral pharmaceutical combination used to treat conditions associated with excessive stomach acid, such as gastroesophageal reflux disease (GERD), gastric and duodenal ulcers, erosive esophagitis, and for the prevention of upper gastrointestinal bleeding in critically ill patients. Omeprazole is a proton pump inhibitor (PPI) that works by irreversibly inhibiting the Gastric H+/K+ ATPase enzyme system on gastric parietal cells, thereby reducing gastric acid secretion. Sodium bicarbonate acts as an antacid by neutralizing existing stomach acid and also serves to protect omeprazole from degradation by stomach acid before absorption[1][2][3][4][5]. The combination allows for rapid onset of action compared to omeprazole alone[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omeprazole + sodium bicarbonate.